Sustained Therapeutics is a clinical stage company developing a drug delivery platform technology initially focused on non-opioid pain medication, but extendable to other APIs including significant oncology indications. Our technology transforms drugs into novel locally injectable delivery systems providing new treatments for chronic and post-surgical pain, fibrotic and inflammatory diseases and cancer. According to independent third party research the market for our first two indications are very large and we have a significant competitive advantage over the current standard of care and other products under development. Targeted injection using our locally injectable delivery systems promises to prolong pain control for one month or longer, allowing treatment of chronic, acute and neuropraxic pain. We have two Phase II trials underway, one in acute pain and the other in chronic pain. Our results to date have been very positive and we look forward to an interim analysis of our Phase II trial in 2023. We plan to move our oncology product into a Phase II clinical trial during late 2023. Our first indication is urothelial cancer, an orphan disease, but we believe that the product is extendable into bladder and other cancer indications as well.